<SEC-DOCUMENT>0001079973-25-001307.txt : 20250814
<SEC-HEADER>0001079973-25-001307.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814185256
ACCESSION NUMBER:		0001079973-25-001307
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80327
		FILM NUMBER:		251221739

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			S.H.N. Financial Investments Ltd.
		CENTRAL INDEX KEY:			0001890802
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		3 ARIK EINSTEIN ST.
		STREET 2:		B ENTRANCE
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4610301
		BUSINESS PHONE:		927(0)779800501

	MAIL ADDRESS:	
		STREET 1:		3 ARIK EINSTEIN ST.
		STREET 2:		B ENTRANCE
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4610301
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001079973-25-000412</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: S.H.N. Financial Investments Ltd. -->
          <cik>0001890802</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/14/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001095981</issuerCik>
        <issuerName>Plus Therapeutics, Inc.</issuerName>
        <issuerCusip>72941H509</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>2710 Reed Rd., Suite 160</com:street1>
          <com:city>Houston</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77051</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>S.H.N. Financial Investments Ltd.</reportingPersonName>
      <citizenshipOrOrganization>L3</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1500000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>1500000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1500000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.51</classPercent>
      <typeOfReportingPerson>FI</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Plus Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2710 Reed Rd., Suite 160, Houston, TX 77051</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>S.H.N. Financial Investments Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Herzliya Hills
Arik Einstein 3, Israel, 4610301</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Israel</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>1,500,000

This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on March 18, 2025, covering 1,209,754 shares of Common Stock purchased on March 4, 2025. The amounts in Row (5), (7) and (9) represent 1,500,000 shares of Common Stock. The percentage set forth on Row (11) of the cover page for the reporting person is based on 99,264,526 shares of Common Stock outstanding as of August 8, 2025, based on the Issuer's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 12, 2025.

Nir Shamir is the Chief Executive Officer of the Reporting Person. As such, Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes.</amountBeneficiallyOwned>
        <classPercent>1.51%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>1,500,000</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>1,500,000</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>S.H.N. Financial Investments Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nir Shamir</signature>
        <title>Nir Shamir, Chief Executive Officer</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
